Xiling Jiang, Ph.D.

UF Postdoctoral Associate (March 2012 to December 2013)

Education:

  • Ph.D. Pharmaceutical Sciences, the State University of New York at Buffalo, Buffalo, NY, 2012
  • M.S. Pharmacology, China Pharmaceutical University, Nanjing, China, 2004
  • B.S. Medicinal Chemistry, China Pharmaceutical University, Nanjing, China, 2001

Biographical Sketch:

Dr. Xiling Jiang received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo, USA in February 2012 under the supervision of Dr. Aiming Yu. Her doctoral thesis was “Indolealkylamine Metabolic Pharmacogenetics, Drug Interactions and Serotonin Toxicity”. She joined the Center for Pharmacometrics and Systems Pharmacology in the Department of Pharmaceutics, College of Pharmacy, University of Florida at Lake Nona (Orlando) as a postdoc associate in March 2012 and has also been working as an ORISE fellow at FDA/CDER/OCP from September 2012 to February 2013. Her work “Development of Physiologically-Based Pharmacokinetic (PBPK) Model of Acetaminophen by Integrating Clinical Pharmacokinetic and In Vitro Enzyme Kinetic Data” was awarded first prize in poster presentation at the 2012 FDA Office of Clinical Pharmacology Science Day. Her work “Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Predicting Drug Metabolism and Pharmacokinetics in Pediatric Populations ─ A Case Study of Acetaminophen” was bestowed with the prestigious “Presidential Trainee Award” presented by the American Society Clinical Pharmacology and Therapeutics (ASCPT) at the 2013 Annual meeting and was selected for oral presentation during the conference. In addition, her work “A CYP2C19 Genotype-Directed Population Pharmacokinetic and Pharmacodynamic Analysis of Clopidogrel in Healthy Adults” has also been presented at various renowned academic and scientific gatherings.

After the completion of her postdoctoral training, she intends to apply her knowledge and training in Pharmacometrics towards rational drug development in the pharmaceutical/biotech industry. Update: She was hired by Johnson & Johnson as a PK/PD Scientist.

Interview with Xiling: http://origin.library.constantcontact.com/download/get/file/1104628606996-295/Jiang_Xiling+Retrospective+Interview.pdf

Testimonial

“Following my PhD from SUNY Buffalo, I joined the Center for Pharmacometrics and System Pharmacology (CPSP) at University of Florida as the first postdoc of the center. Great faculty members, an open atmosphere, excellent colleagues from all over the world, fascinating projects, and most importantly, close collaboration with world-class investigators from academia, regulatory agencies and industries, made for this unique training opportunity. It has been extremely rewarding to engage in research at CPSP and to further research projects in the area of pediatric drug development and personalized medicine. I am so grateful that I received plenty of opportunities to present my research at various scientific settings, including FDA Science Day, ASCPT and ACCP Annual meetings, where my research was recognized by fellow researchers and received multiple awards. This strongly encouraged me to continue with my ongoing interest in applying mechanistic modeling towards the optimization of efficacy and safety of medications, particularly in understudied populations. My training experience at the Center expanded my knowledge on pharmacometrics, clinical pharmacology, regulatory science and drug development, which has been truly rewarding and set the stage for a successful career.” – Xiling Jiang, Ph.D.  

Selected Publications

Book Chapters:

Jiang XL, Yu AM. Genetically modified mouse models in ADME studies. In Zhang D and Surapaneni S (ed). ADME-Enabling Technologies in Drug Design and Development. Wiley, Hoboken, NJ; 2012.

Journal Articles:

Jiang XL, Shen HW, Mager DE, Yu AM. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos. 2013 Feb 7. [Epub ahead of print].

Shen HW, Jiang XL, Yu AM. Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice.

Drug Metab Dispos. 2011 Jul;39(7):1227-34.

Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev. 2011 Feb;43(1):27-40.

Jiang XL, Shen HW, Yu AM. Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos. 2009 Mar;37(3):443-6.

Poster Presentations:

Jiang XL, Zhao P, Lesko LJ, Schmidt S. Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Predicting Drug Metabolism and Pharmacokinetics in Pediatric Populations ─ A Case Study of Acetaminophen. ASCPT 2013 Annual meeting, (Mar. 2013)

Jiang XL, Horenstein RB, Shuldiner AR, Yerges-Armstrong LM, Lesko LJ, Schmidt S. A CYP2C19 Genotype-Directed Population Pharmacokinetic and Pharmacodynamic Analysis of Clopidogrel in Healthy Adults. ASCPT 2013 Annual meeting, (Mar. 2013)

Jiang XL, Zhao P, Lesko LJ, Schmidt S. Development of Physiologically-Based Pharmacokinetic (PBPK) Model of Acetaminophen by Integrating Clinical Pharmacokinetic and In Vitro Enzyme Kinetic Data. FDAOffice of Clinical Pharmacology Science Day, (Sep. 2012)

Oral Presentations:

Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Predicting Drug Metabolism and Pharmacokinetics in Pediatric Populations ─ A Case Study of Acetaminophen. ASCPT 2013 Annual meeting, (Mar. 8th, 2013)

Personalizing Antiplatelet Therapy ─ Development of a CYP2C19 Genotype-Directed Dosing Algorithm for Clopidogrel. University of Maryland (Nov. 28th, 2012)